Our Achievements
-
Collaborations with Royal United Hospitals Bath, University of Birmingham, Genomics Institute at the University of Birmingham, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University NDORMS, London School of Hygiene and Tropical Medicine, Kings College London, University of Exeter, University College London, the Alzheimer’s Society, British Heart Foundation, Royal Marsden Hospital and Cancer Research UK.
-
Commercial partnerships with the global pharmaceutical Bayer, Kinetix and Synetic, including winning an internal innovation award in Bayer.
-
One published research paper in collaboration with the The Royal United Hospital for Rheumatic Diseases – titled “Back pain, ankylosing spondylitis and social media usage; a descriptive analysis of current activity” in Rheumatology International. Three further papers in draft or peer review.
-
University Hospitals Birmingham NHS Trust, focused on Hypertrophic Cardiomyopathy early signs and symptoms with the aim of accelerating diagnosis.
-
Clinical Bioinformatics at the Genomics Institute at the University of Birmingham to map phenotypes discussed by patients within social conversation back to genetics to improve the diagnosis of rare diseases. "Talking about diseases: developing a social media digital phenotype to represent public perspectives on disease." Currently in clinical validation phase.
-
University of Oxford, focused on Fibromyalgia.
For the full details of our achievements, please see our Trustee reports. These include:
-
Attracting over £1m of funding
-
Growth of worldwide volunteers from zero to 130
-
Winning a place on the London NHS Accelerator Programme – reaching the final 20 from 169 applicants, for our Million Minds Patient-facing App
-
Conducting numerous trainings for pharmaceutical and health care commercial clients on the role social data can play to gain a unique and valuable insight into patients’ experiences, including Learn with Nurses sharing equity in cardiovascular care insights.
-
Achieving a finalist position in 2019 Europe’s Digital Top 50, out of 550 entrant organisations, as judged by Google, McKinsey, Rocket and INSEAD, recognising White Swan’s start-up potential.
-
Uncovering patient insights across disease areas including oncology, dementia, hypertrophic cardiomyopathy and other cardiology areas, fibromyalgia, ankylosing spondylitis, long covid, mental health, central post stroke syndrome, and the prediction of accident and emergency admission rates.
-
Our development of Million Minds as a patient-facing app has reach proof-of-concept stage with diagnostic model including 600 conditions and 6000 symptoms. It has been tested with 140 real patient profiles and 3000 synthetically generated profiles, delivering an 86% accuracy based on the strength of association between symptoms and conditions from both expert knowledge and trends seen within a dataset of 200 million social conversations.
-
The appointment of an advisory board for the further development of Million Minds as a patient-facing app, including a Professor in Clinical Data Science and a GP advising Public Health England.
-
Shortlisted for a share of £4m UK Space Agency/NHS/European Space Agency grant to develop an application to meet mental health needs (2019).
-
Analysed 44,000 research papers related to Coronavirus, pro-bono, to facilitate work of clinicians and researchers to search for answers during the 2020 pandemic. Following this analysed trends in 5million online conversations relating to Long Covid for a Professor of Clinical Data Science at UCL, to inform future care strategy.
-
Presentations and panel discussions at DigitalHealth AI&Data 2022, Nichollas Hall's CHC European Conference, Pharma Integrates 2023. Participated in two Learn With Nurses webinars in 2023. Invited to present at IIEX 2024 and Digital Rewired 2024.
To find out more about the above or any of our work please contact hello@whiteswan.org.uk
